Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Follicular 1

Interventions

Specimen Handling 132 Magnetic Resonance Spectroscopy 107 Biopsy 79 pembrolizumab 66 Nivolumab 63 Carboplatin 62 Cisplatin 60 Cyclophosphamide 56 Paclitaxel 47 Radiotherapy 37 Gemcitabine 37 Bevacizumab 36 Dexamethasone 33 Pemetrexed 28 Rituximab 27 Fluorouracil 27 Doxorubicin 26 olaparib 25 Injections 25 fludarabine 24 durvalumab 24 atezolizumab 24 Radiation 24 Ipilimumab 23 Docetaxel 23 Oxaliplatin 22 Cytarabine 22 venetoclax 21 Vincristine 21 Taxes 21

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × orelabrutinib × 30 days × Clear all

NCT07585747 2026-05-14

CUREMZL002

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Not yet recruiting

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡